Moderna 2020 earnings preview: 3 things to consider
Moderna Inc will announce its full-year and fourth quarter earnings today. Here are some things for investors to note in the meantime.
- Moderna Inc (NASDAQ: MRNA) share price is up nearly 30% so far in 2021
- The biotechnology company is scheduled to release its Q4 and full-year earnings for fiscal 2020 today
- Analysts are expecting an improvement in adjusted loss per share for the quarter
- They will also be paying close attention to Moderna’s Q1 2021 revenue guidance
- Trade Moderna shares, long or short, with an IG account
US biotechnology company Moderna Inc is scheduled to report its fourth quarter and full-year results for the 2020 financial year, before the market opens on Thursday (25 February 2021).
Below are some things for investors to consider ahead of the earnings release.
1. Moderna’s share price is up 30% year-to-date
Moderna’s shares are up some 29.6% so far this year, all thanks to the approval and roll-out of its Covid-19 vaccine, mRNA-1273, across North America, Europe and parts of Asia-Pacific and the Middle East.
Prior to mRNA-1273, Moderna had never introduced an approved drug to the market.
In the last one year, the US drug developer’s share price has skyrocketed over 450%, as vaccine news and higher revenue expectations kept driving stock prices upwards.
Moderna shares hit a peak price of US$186 on 08 February 2021. Share price has fallen roughly 22.2% since then, after the company said it was facing shipment delays for the vaccine.
Nevertheless, the company is still expecting to deliver 100 million doses by the end of Q1 2021.
2. Analysts forecast adjusted loss of US$0.22 against US$0.31 in 2019
Wall Street brokers polled by Refinitiv are expecting adjusted earnings per share (EPS) to hit a loss of US$0.22, as against an adjusted loss per share of US$0.31 recorded in the same quarter in fiscal 2019.
For the full year, analysts are forecasting an adjusted loss per share of US$1.32, up from an actualised loss per share of US$1.55 in FY2019.
Sales in the fourth quarter of FY2021 are also expected to grow a massive 2,170% year-over-year, which will surpass any quarterly growth figures in the last few years. The consensus Q4 revenue estimate stands at US$279.4 million.
For the full year, analysts have given a consensus estimate of US$534.9 million, up over 800% from 2019’s reported sales of US$60.2 million. The final revenue figure was lower than Wall Street estimates of US$75.4 million.
Analysts will also be paying close attention to Moderna’s Q1 2021 revenue and profit guidance, being that the market has been extremely optimistic about the company’s financial results with vaccine deployments now in full swing.
3. Moderna posted 830% revenue increase in Q3
Moderna posted a total revenue of US$157.9 million in the third quarter of 2020 for the three months ended 30 September 2020, an increase of 830% from the US$17 million recorded for the same period in 2019.
Total revenue was US$232.7 million for the nine months ended 30 September 2020 compared to US$46.2 million for the same period in 2019.
Total revenue increased for both the three month and nine month periods in 2020, thanks to increases in grant revenue, primarily due to the company’s Biomedical Advanced Research and Development Authority (BARDA) agreement related to its mRNA-1273 vaccine candidate development.
However, Q3 2020 net loss came in at US$233.6 million, an increase from US$123.2 million for the same period in 2019. The company had attributed this to higher research and development as well as general and administrative expenses in relation to mRNA-1273’s development.
How to trade Moderna stocks with IG
Are you feeling bullish or bearish on Moderna’s stocks?
- Create a live or demo IG Trading Account, or log in to your existing account
- Enter <Moderna Inc> in the search bar and select the instrument
- Choose your position size
- Click on ‘buy’ or ‘sell’ in the deal ticket
- Confirm the trade
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
Please see important Research Disclaimer.
Look closer this US earnings season
Discover opportunities with using our award-winning technology* and range of educational resources.
- Get expert analysis on upcoming announcements
- Set automated alerts to never miss an opportunity
- Choose from 16,000+ shares with our stock screener
* Based on the Investment Trends 2018 Singapore CFD & FX Report based on a survey of over 4,500 traders and investors. Awarded the Best Online Trading Platform by Influential Brands in 2021.
Live prices on most popular markets
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.